Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$0.66 USD
+0.03 (4.89%)
Updated Apr 26, 2024 03:58 PM ET
After-Market: $0.66 0.00 (0.27%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth C Momentum C VGM
Income Statements
Fiscal Year end for Monopar Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 9 | 11 | 9 | 7 | 4 |
Income After Depreciation & Amortization | -9 | -11 | -9 | -7 | -4 |
Non-Operating Income | 0 | 0 | 0 | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -8 | -11 | -9 | -6 | -4 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -8 | -11 | -9 | -6 | -4 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -8 | -11 | -9 | -6 | -4 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -9 | -11 | -9 | -7 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -11 | -9 | -7 | -4 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 13.82 | 12.65 | 12.47 | 10.86 | 9.32 |
Diluted EPS Before Non-Recurring Items | -0.61 | -0.83 | -0.73 | -0.58 | -0.45 |
Diluted Net EPS (GAAP) | -0.61 | -0.83 | -0.73 | -0.58 | -0.45 |
Fiscal Year end for Monopar Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 1.92 | 2.07 | 2.32 | 2.52 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -1.92 | -2.07 | -2.32 | -2.52 |
Non-Operating Income | NA | 0.10 | 0.11 | 0.13 | 0.09 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -1.81 | -1.95 | -2.20 | -2.43 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -1.81 | -1.95 | -2.20 | -2.43 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -1.81 | -1.95 | -2.20 | -2.43 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 15.00 | 14.12 | 13.42 | 13.11 |
Diluted EPS Before Non-Recurring Items | NA | -0.12 | -0.14 | -0.16 | -0.19 |
Diluted Net EPS (GAAP) | NA | -0.12 | -0.14 | -0.16 | -0.19 |